Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modelling Study

Implementation of long-acting antiretroviral therapy in low-income and middle-income countries

(2022) Fiona V. Cresswell et al.   Current Opinion in HIV and AIDS

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

(2021) Daryl Hodge et al.   CLINICAL PHARMACOKINETICS

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

(2021) Chloe Orkin et al.   Lancet HIV

Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics

(2020) Shetty Ravi Dyavar et al.   Scientific Reports

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

(2020) Raphael J Landovitz et al.   Lancet HIV

Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics

(2020) Zubida M. Al‐Majdoub et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

(2018) Mohamad Shebley et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes

(2018) Felix Stader et al.   CLINICAL PHARMACOKINETICS

Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects

(2018) Vikas K. Dawra et al.   CLINICAL THERAPEUTICS

Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling

(2018) Rajith K R Rajoli et al.   JOURNAL OF INFECTIOUS DISEASES

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

(2016) Manel Aouri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks

(2015) Kimberly K. Scarsi et al.   CLINICAL INFECTIOUS DISEASES

Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

(2015) Christian Wagner et al.   CLINICAL PHARMACOKINETICS

Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration

(2014) Christian Wagner et al.   CLINICAL PHARMACOKINETICS

Effect of Rifampin and Rifabutin on the Pharmacokinetics of Lersivirine and Effect of Lersivirine on the Pharmacokinetics of Rifabutin and 25-O-Desacetyl-Rifabutin in Healthy Subjects

(2012) Manoli Vourvahis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover

(2011) K. Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES